# Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

> **NCT04309981** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sara V. Latorre** · enrollment: 73 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Adult differentiated autologous T-cells with anti-BCMA specificity

## Key facts

- **NCT ID:** NCT04309981
- **Lead sponsor:** Sara V. Latorre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-27
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309981, "Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04309981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*